Heterogeneity of invasive ductal carcinoma: Proposal for a hypothetical classification

Journal of Korean Medical Science

Volumn 21, Issue 3, 2006, Pages 460-468

  Jo, Baik Hyeon ^a   Chun, Yi Kyeong ^b  

^a Mizmedi Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Carcinogenesis; Carcinoma, Ductal, Breast; Heterogeneity; Nuclear Grade; Receptors, Estrogen; Receptors, Progesterone

Indexed keywords

EID: 33745278048     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.3.460     Document Type: Article

References (30)

1. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Crosignani P, Danzon A, Federico M, Gafa L, Grosclaude P, Hedelin G, Mace-Lesech J, Garcia CM, Moller H, Paci E, Raverdy N, Tretarre B, Williams EM; European Concerted Action on Survival and Care of Cancer Patients (EUROCARE) Working Group. Breast carcinoma survival in Europe and the United States. Cancer 2004; 100: 715-22.
2. Bloom HJ, Richardson WW, Harries EJ. Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J 1962; 5299: 213-21.
3. Johnstone PA, Norton MS, Riffenburgh RH. Survival of patients with untreated breast cancer. J Surg Oncol 2000; 73: 273-7.
4. Fox MS. On the diagnosis and treatment of breast cancer. JAMA 1979; 241: 489-94.
5. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
6. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994; 32: 5-12.
7. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 1999; 187: 396-402.
8. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10-26.
9. Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol 2000; 18: 591-9.
10. Clark GM. Prognostic factors and Predictive Factors. In Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. Philadelphia, Lippincott Williams & Wilkins 2000; 489: 514.
11. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980; 15: 239-51.
12. Bose S, Mohammed M, Shintaku P, Rao PN. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J 2001; 7: 337-44.
13. Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002; 82; 737-46.
14. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203: 661-71.
15. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998; 90: 697-703.
16. Farabegoli F, Champeme MH, Bieche I, Santini D, Ceccarelli C, Derenzini M, Lidereau R. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002; 196: 280-6.
17. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.
18. Silverberg SG, Chitale AR. Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast. Cancer 1973; 32: 830-7.
19. Lampejo OT, Barnes DM, Smith P, Millis RR. Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol 1994; 11: 215-22.
20. Elston CW, Gresham GA, Rao GS, Zebro T, Haybittle JL, Houghton J, Kearney G. The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects). Br J Cancer 1982; 45: 655-69.
21. Heimann R, Hellman S. Individual characterisation of the metastatic capacity of human breast carcinoma. Eur J Cancer 2000; 36: 1631-9.
22. Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, Sauer H, Senn HJ, Holzel D. The process of metastasisation for breast cancer. Eur J Cancer 2003; 39: 1794-806.
23. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957; 105: 97-102.
24. Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol 2001; 115: 709-18.
25. Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology 1996; 29: 397-409.
26. Moreno A, Lloveras B, Figueras A, Escobedo A, Ramon JM, Sierra A, Fabra A. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Mod Pathol 1997; 10: 1088-92.
27. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
28. Van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991-6.
29. Man YG, Tai L, Barner R, Vang R, Saenger JS, Shekitka KM, Bratthauer GL, Wheeler DT, Liang CY, Vinh TN, Strauss BL. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res 2003; 5: R231-41.
30. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-82.